1] Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC) and Departamento de Biología Molecular, Universidad de Cantabria, CSIC, SODERCAN, Santander, Spain [2] Servicio de Hematología, Hospital U. Marqués de Valdecilla, and IFIMAV-FMV, Santander, Spain.
Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC) and Departamento de Biología Molecular, Universidad de Cantabria, CSIC, SODERCAN, Santander, Spain.
Oncogene. 2015 Jan 8;34(2):246-56. doi: 10.1038/onc.2013.535. Epub 2013 Dec 23.
BCL6 is a zinc-finger transcriptional repressor, which is highly expressed in germinal centre B-cells and is essential for germinal centre formation and T-dependent antibody responses. Constitutive BCL6 expression is sufficient to produce lymphomas in mice. Deregulated expression of BCL6 due to chromosomal rearrangements, mutations of a negative autoregulatory site in the BCL6 promoter region and aberrant post-translational modifications have been detected in a number of human lymphomas. Tight lineage and temporal regulation of BCL6 is, therefore, required for normal immunity, and abnormal regulation occurs in lymphomas. CCCTC-binding factor (CTCF) is a multi-functional chromatin regulator, which has recently been shown to bind in a methylation-sensitive manner to sites within the BCL6 first intron. We demonstrate a novel CTCF-binding site in BCL6 exon1A within a potential CpG island, which is unmethylated both in cell lines and in primary lymphoma samples. CTCF binding, which was found in BCL6-expressing cell lines, correlated with the presence of histone variant H2A.Z and active histone marks, suggesting that CTCF induces chromatin modification at a transcriptionally active BCL6 locus. CTCF binding to exon1A was required to maintain BCL6 expression in germinal centre cells by avoiding BCL6-negative autoregulation. Silencing of CTCF in BCL6-expressing cells reduced BCL6 mRNA and protein expression, which is sufficient to induce B-cell terminal differentiation toward plasma cells. Moreover, lack of CTCF binding to exon1A shifts the BCL6 local chromatin from an active to a repressive state. This work demonstrates that, in contexts in which BCL6 is expressed, CTCF binding to BCL6 exon1A associates with epigenetic modifications indicative of transcriptionally open chromatin.
BCL6 是一种锌指转录抑制剂,在生发中心 B 细胞中高度表达,是生发中心形成和 T 依赖性抗体反应所必需的。BCL6 的组成性表达足以在小鼠中产生淋巴瘤。在许多人类淋巴瘤中,已经检测到由于染色体重排、BCL6 启动子区域负自调节位点的突变和异常的翻译后修饰导致的 BCL6 表达失调。BCL6 的严格谱系和时间调节对于正常免疫是必需的,而异常调节则发生在淋巴瘤中。CCCTC 结合因子(CTCF)是一种多功能染色质调节剂,最近已被证明以甲基化敏感的方式结合到 BCL6 第一内含子内的位点。我们在潜在的 CpG 岛内的 BCL6 外显子 1A 内发现了一个新的 CTCF 结合位点,该位点在细胞系和原发性淋巴瘤样本中均未甲基化。在表达 BCL6 的细胞系中发现的 CTCF 结合与组蛋白变体 H2A.Z 和活性组蛋白标记物的存在相关,这表明 CTCF 在转录活跃的 BCL6 基因座诱导染色质修饰。CTCF 结合到外显子 1A 是避免 BCL6 负自调节以维持生发中心细胞中 BCL6 表达所必需的。在表达 BCL6 的细胞中沉默 CTCF 会降低 BCL6 mRNA 和蛋白表达,这足以诱导 B 细胞向浆细胞的终末分化。此外,缺乏 CTCF 与外显子 1A 的结合会将 BCL6 局部染色质从活跃状态转变为抑制状态。这项工作表明,在表达 BCL6 的情况下,CTCF 结合到 BCL6 外显子 1A 与指示转录开放染色质的表观遗传修饰相关联。